Skip to Content

Colistimethate Pregnancy and Breastfeeding Warnings

Colistimethate is also known as: Coly Mycin M

Medically reviewed on Apr 19, 2017

Colistimethate Pregnancy Warnings

Colistimethate has been assigned to pregnancy category C by the FDA. In animal studies, colistimethate was teratogenic and embryotoxic in rabbits, but not teratogenic in rats. There are no controlled data in human pregnancy. Colistimethate crosses the placenta and should only be given during pregnancy when benefit outweighs risk.

See references

Colistimethate Breastfeeding Warnings

Colistimethate is excreted into human milk in small amounts (milk-to-plasma ratio 0.17 to 0.18). The possibility of bowel flora modification and interference with culture results should be considered. The manufacturer recommends that caution be used when administering colistimethate to breast-feeding women.

See references

References for pregnancy information

  1. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 7th ed." Philadelphia, PA: Lippincott Williams & Wilkins (2005):
  2. "Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis, Morris Plains, NJ.

References for breastfeeding information

  1. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 7th ed." Philadelphia, PA: Lippincott Williams & Wilkins (2005):
  2. "Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis, Morris Plains, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide